CORE Biomedicine

$21.0M Series A

Announced: Jul 28, 2026
Sector: Biotechnology
Investors: 9

Summary

CORE Biomedicine completed a $21 million Series A financing led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with additional investors participating. The company also received an AMED grant award to support its cancer therapeutics development. CORE Biomedicine is a biotechnology company.

Investors

UTokyo Innovation Platform Co., Ltd., Elikon Venture, InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., Root Venture Partners